Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Savannah, GA
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigator Site
mi
from
Evansville, IN
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigator Site
mi
from
Evansville, IN
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Bowling Green, KY
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Bowling Green, KY
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigator Site
mi
from
Owensboro, KY
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigator Site
mi
from
Owensboro, KY
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis
mi
from
Baltimore, MD
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Columbia, MD
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Columbia, MD
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Waldorf, MD
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Waldorf, MD
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Novi, MI
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Novi, MI
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigator Site
mi
from
Minneapolis, MN
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Billings, MT
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Billings, MT
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Omaha, NE
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Papillion, NE
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Papillion, NE
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Brooklyn, NY
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Mineola, NY
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Cleveland, OH
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Medford, OR
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Medford, OR
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Philadelphia, PA
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigator Site
mi
from
Lincoln, RI
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigator Site
mi
from
Lincoln, RI
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Summerville, SC
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Summerville, SC
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Arlington, TX
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Salt Lake City, UT
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis
mi
from
Fairfax, VA
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis
mi
from
Fairfax, VA
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Everett, WA
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Everett, WA
Click here to add this to my saved trials
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated:  1/15/2015
Novartis Investigative Site
mi
from
Spokane, WA
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled Study With Exploratory DR to Investigate the Efficacy and Safety of 16 Wks Treatment With s.c. QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists
Status: Enrolling
Updated: 1/15/2015
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma
Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma
Status: Enrolling
Updated:  4/23/2015
Ohio State University
mi
from
Columbus, OH
Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma
Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma
Status: Enrolling
Updated: 4/23/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Status: Enrolling
Updated:  5/5/2015
Nemours Children's Clinic
mi
from
Jacksonville, FL
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Status: Enrolling
Updated: 5/5/2015
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Status: Enrolling
Updated:  5/5/2015
Nemours Children's Hospital/Dept of Pulmonology
mi
from
Orlando, FL
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Status: Enrolling
Updated: 5/5/2015
Nemours Children's Hospital/Dept of Pulmonology
mi
from
Orlando, FL
Click here to add this to my saved trials
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Status: Enrolling
Updated:  5/5/2015
University of South Florida, Morsani College of Medicine
mi
from
Tampa, FL
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Status: Enrolling
Updated: 5/5/2015
University of South Florida, Morsani College of Medicine
mi
from
Tampa, FL
Click here to add this to my saved trials
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Status: Enrolling
Updated:  5/18/2015
Baylor College of Medicine
mi
from
Houston, TX
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Status: Enrolling
Updated: 5/18/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Positive Airway Pressure for the Treatment of Asthma
Positive Airway Pressure for the Treatment of Asthma
Status: Enrolling
Updated:  7/20/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Positive Airway Pressure for the Treatment of Asthma
Positive Airway Pressure for the Treatment of Asthma
Status: Enrolling
Updated: 7/20/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site
mi
from
Huntington Beach, CA
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10133
mi
from
Denver, CO
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10133
mi
from
Denver, CO
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10180
mi
from
Gainesville, GA
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10180
mi
from
Gainesville, GA
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site
mi
from
Louisville, KY
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10158
mi
from
Bethesda, MD
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10158
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10177
mi
from
Wheaton, MD
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10177
mi
from
Wheaton, MD
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10131
mi
from
Minneapolis, MN
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10131
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10531
mi
from
Plymouth, MN
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10531
mi
from
Plymouth, MN
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site
mi
from
St. Louis, MO
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10118
mi
from
Bellevue, NE
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10118
mi
from
Bellevue, NE
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10155
mi
from
Skillman, NJ
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10155
mi
from
Skillman, NJ
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10112
mi
from
Rochester, NY
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10112
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10105
mi
from
High Point, NC
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10105
mi
from
High Point, NC
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10522
mi
from
Canton, OH
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10522
mi
from
Canton, OH
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site
mi
from
Cincinnati, OH
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated:  8/12/2015
Teva Investigational Site 10132
mi
from
Eugene, OR
Safety Study of Albuterol Spiromax® in Subjects With Asthma
A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma
Status: Enrolling
Updated: 8/12/2015
Teva Investigational Site 10132
mi
from
Eugene, OR
Click here to add this to my saved trials